CREYON

Medical and scientific research in the field of Oligonucleotide-Based Medicines; Oligonucleotide-Based drug development services; engineering and chemical synthesis of oligonucleotide-based medicines and their building blocks and delivery technologies; engineering and chemical synthesis of oligonucleotide therapeutics and their building blocks and delivery technologies; experimental assessment of pharmacological and chemical properties of oligonucleotide-base medicines in the nature of pharmaceutical research and development; designing clinical trial studies for others; providing medical and scientific research information in the fields of Oligonucleotide-Based Medicine clinical trials; platform as a service (PaaS) featuring computer software platforms for data creation and collection using artificial intelligence for precision medicine, namely, to decode diseases, develop targeted Oligonucleotide-Based Medicine treatments and therapies, and to select patients that will respond to Oligonucleotide-Based Medicine treatments and therapies; platform as a service (PaaS) featuring computer software platforms for data creation and collection using artificial intelligence for big data analytics, predictive data analytics, and predictive modeling, and multivariate analytics; platform as a service (PaaS) featuring data creation and collection tools, computer platforms and software using artificial intelligence for bioinformatics, simulations in clinical trials or studies, the designing of clinical trials or studies, and the de-risking of clinical trial or study designs and clinical trials simulations